|
|
News Breaks | | | | August 16, 2012 | | 08:57 EDT |  | ACHN, IDIX | Achillion jumps 5% to $6.20 after FDA puts hold on Idenix trial
Achillion (ACHN) has a drug candidate for the treatment of hepatitis C. | |
|
News For ACHN;IDIX From The Last 14 Days Check below for free stories on ACHN;IDIX the last two weeks. |
|
|
| May 16, 2013 | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
 Subscribe for More Information | | | May 15, 2013 | | 06:06 EDT | | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | | | May 7, 2013 | | 06:08 EDT |  | ACHN | Achillion reports Q1 EPS (14c), consensus (15c)
Subscribe for More Information | |
|
|
|
|
|
|
